Heba Youssef: Can Cefoperazone Cause Coagulopathy?
Heba Youssef, Clinical Nutrition Pharmacist at Helwan General Hospital, shared a post on LinkedIn:
”Cefoperazone can cause a coagulopathy that’s easy to miss. Its NMTT side chain interferes with vitamin K-dependent clotting factors, and in some patients this is made worse by suppression of gut flora that normally produces vitamin K. The result, hypoprothrombinemia, can happen with or without visible bleeding, which is exactly why it needs active monitoring rather than waiting for symptoms.
Patients at higher risk include those with poor nutrition, malabsorption, liver or biliary disease, kidney dysfunction, prolonged or high-dose therapy, or concurrent use of anticoagulants. For these patients, checking baseline and repeat PT/INR and platelet counts is a simple but important safety step.
Giving vitamin K to every patient on cefoperazone isn’t routinely recommended, since the evidence doesn’t support one standard approach. But vitamin K should be given once deficiency or drug-related coagulopathy is suspected or confirmed. A 2024 randomized trial found that 10 mg IV vitamin K weekly reduced coagulopathy and bleeding in high-risk ICU patients, an encouraging finding, though still from a single study rather than an established guideline.
If PT/INR rises unexpectedly during cefoperazone therapy, check for vitamin K deficiency and other causes before blaming the drug alone. And if bleeding continues with no other explanation, that’s a clear signal to stop the drug and follow your institution’s protocol.
References:
- FDA. CEFOBID® (cefoperazone) Prescribing Information. Revised March
- Miao W, Guo J, Cheng H, et al. Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder. Infect Drug Resist. 2023;16:6277–6284.
- Ebid AI, Abdeen HA, Maher RM, Mohamed-Abdel-Motaleb SM. Cefoperazone-Sulbactam-Induced Coagulopathy in Critically Ill Egyptian Patients: Role of Vitamin K Prophylactic Doses. Hosp Pharm.
- Strom BL, Schinnar R, Gibson GA, Brennan PJ, Berlin JA. Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf. ”

Other posts featuring Heba Youssef on Hemostasis Today.
-
Nov 14, 2026, 00:23Saji Kumar: The Role of Agentic AI in Blood Bank Inventory Coordination
-
Nov 14, 2026, 00:04Carlos A. Metidieri Menegozzo: The First Priority in Trauma Transfusion May Be Time to First Blood Product
-
Nov 13, 2026, 23:43Alamgir Hosen Ronit: Corrected Platelet Count in EDTA Induced Platelet Aggregation
-
Nov 13, 2026, 23:32Evi Loos: Can PRP Improve Pain in Thumb Base Osteoarthritis?
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders